HIV Vaccines Based on Novel MULV-HIV Fusion Proteins.
Abstract
We have continued our efforts to characterize the immunological properties of the Vl/V2 domain of HIV-l gp120. Studies with human sera and with antibodies isolated from immunized animals have shown that the Vl/V2 domain contains highly conserved epitopes that can act as potent neutralizing targets for a broad range of primary HIV-l isolates. We have prepared two prototype immunogens, based on the Case-A2 and SF-162 isolates. The Case-A2 isolate contains the clade B V2 consensus sequence, and this antigen induces highly cross reactive anti-V1/V2 antibodies in both rats and macaques that possess potent cross-neutralizing activity for several primary HIV-1 isolates. Our studies to date have shown that while the V1/V2 domain remains an intriguing target for viral neutralization and a candidate for HIV vaccine development, additional modification of the V1/V2 fusion proteins is needed to improve their specifications and efficiencies as vaccines capable of inducing relevant neutralizing responses.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 1999
- Accession Number
- ADA373677
Entities
People
- Abraham Pinter
Organizations
- Public Health Research Institute